Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Taxotere

TAXOTERE 20 mg/0.5 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 11–12

HOS-084537 · Präparat HOS-083047

11 The pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not influenced by their co-administration. Limited data from a single uncontrolled study were suggestive of an interaction between docetaxel and carboplatin. When combined to docetaxel, the clearance of carboplatin was about 50% higher than values previously reported for carboplatin monotherapy.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carboplatin (HOS-084540) cyclophosphamide (HOS-084539) doxorubicin (HOS-084538)

Wechselwirkungen · Taxotere

TAXOTERE 80 mg/2 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 55–56

HOS-084653 · Präparat HOS-083047

55 The pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not influenced by their co-administration. Limited data from a single uncontrolled study were suggestive of an interaction between docetaxel and carboplatin. When combined to docetaxel, the clearance of carboplatin was about 50% higher than values previously reported for carboplatin monotherapy.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carboplatin (HOS-084540) cyclophosphamide (HOS-084539) doxorubicin (HOS-084538)

Wechselwirkungen · Taxotere

TAXOTERE 20 mg/1 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 100

HOS-084767 · Präparat HOS-083047

The pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not influenced by their co-administration. Limited data from a single uncontrolled study were suggestive of an interaction between docetaxel and carboplatin. When combined to docetaxel, the clearance of carboplatin was about 50% higher than values previously reported for carboplatin monotherapy.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carboplatin (HOS-084540) cyclophosphamide (HOS-084539) doxorubicin (HOS-084538)

Wechselwirkungen · Taxotere

TAXOTERE 80 mg/4 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 144–145

HOS-084879 · Präparat HOS-083047

144 The pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not influenced by their co-administration. Limited data from a single uncontrolled study were suggestive of an interaction between docetaxel and carboplatin. When combined to docetaxel, the clearance of carboplatin was about 50% higher than values previously reported for carboplatin monotherapy.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carboplatin (HOS-084540) cyclophosphamide (HOS-084539) doxorubicin (HOS-084538)

Wechselwirkungen · Taxotere

TAXOTERE 160 mg/8 mL concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 189–190

HOS-084989 · Präparat HOS-083047

189 The pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not influenced by their co-administration. Limited data from a single uncontrolled study were suggestive of an interaction between docetaxel and carboplatin. When combined to docetaxel, the clearance of carboplatin was about 50% higher than values previously reported for carboplatin monotherapy.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carboplatin (HOS-084540) cyclophosphamide (HOS-084539) doxorubicin (HOS-084538)

Gegenanzeigen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.3 · PDF-Seite 6

HOS-085565 · Präparat HOS-083155

Hypersensitivity to the active substance, peanut or soya, or to any of the excipients listed in section 6.1.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Gegenanzeigen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.3 · PDF-Seite 6

HOS-085566 · Präparat HOS-083155

Caelyx pegylated liposomal must not be used to treat AIDS-KS that may be treated effectively with local therapy or systemic alfa-interferon.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9

HOS-085567 · Präparat HOS-083155

No formal medicinal product interaction studies have been performed with Caelyx pegylated liposomal, although phase II combination trials with conventional chemotherapy agents have been conducted in patients with gynaecological malignancies. Exercise caution in the concomitant use of medicinal products known to interact with standard doxorubicin hydrochloride. Caelyx pegylated liposomal, like other doxorubicin hydrochloride preparations, may potentiate the toxicity of other anti-cancer therapies. During clinical trials in patients with solid tumours (including breast and ovarian cancer) who have received concomitant cyclophosphamide or taxanes, no new additive toxicities were noted. In patients with AIDS, exacerbation of cyclophosphamide-induced haemorrhagic cystitis and enhancement of the hepatotoxicity of 6-mercaptopurine have been reported with standard doxorubicin hydrochloride. Caution must be exercised when giving any other cytotoxic agents, especially myelotoxic agents, at the same time.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): mercaptopurine (HOS-085568) cyclophosphamide (HOS-084539)

Nebenwirkungen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10

HOS-085569 · Präparat HOS-083155

Summary of the safety profile The most frequent adverse reactions (≥ 20%) were neutropaenia, nausea, leukopaenia, anaemia, and fatigue.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10

HOS-085570 · Präparat HOS-083155

Severe adverse reactions (Grade 3/4 adverse reactions occurring in ≥ 2% of patients) were neutropaenia, PPE, leukopaenia, lymphopaenia, anaemia, thrombocytopaenia, stomatitis, fatigue, diarrhoea, vomiting, nausea, pyrexia, dyspnoea, and pneumonia. Less frequently reported severe adverse reactions included Pneumocystis jirovecii pneumonia, abdominal pain, cytomegalovirus infection including cytomegalovirus chorioretinitis, asthenia, cardiac arrest, cardiac failure, cardiac failure congestive, pulmonary embolism, thrombophlebitis, venous thrombosis, anaphylactic reaction, anaphylactoid reaction, toxic epidermal necrolysis, and Stevens-Johnson syndrome.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10

HOS-085571 · Präparat HOS-083155

Tabulated list of adverse reactions Table 5 summarises the adverse drug reactions that occurred in patients receiving Caelyx pegylated liposomal in 4,231 patients for the treatment of breast cancer, ovarian cancer, multiple myeloma, and AIDS-related KS. Post-marketing adverse reactions are also included, as indicated by “b”. Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (frequency cannot be estimated from the available data). Within each frequency grouping, where relevant, adverse reactions are presented in order of decreasing seriousness.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10

HOS-085572 · Präparat HOS-083155

Table 5: Adverse reactions in patients treated with Caelyx pegylated liposomal System Organ Class Frequency All Grades Adverse Drug Reaction

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10

HOS-085573 · Präparat HOS-083155

Infections and Common Sepsis infestations Pneumonia Pneumocystis jirovecii pneumonia Cytomegalovirus infection including cytomegalovirus chorioretinitis Mycobacterium avium complex infection Candidiasis Herpes zoster Urinary tract infection Infection Upper respiratory tract infection Oral candidiasis Folliculitis Pharyngitis Nasopharyngitis Uncommon Herpes simplex Fungal infection Rare Opportunistic infection (including Aspergillus, Histoplasma, Isospora,

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10–11

HOS-085574 · Präparat HOS-083155

10  Legionella, Microsporidium, Salmonella, Staphylococcus, Toxoplasma, Tuberculosis)a Neoplasms benign, Not known Acute myeloid leukaemiab malignant and Myelodysplastic syndromeb unspecified (including Oral neoplasmb cysts and polyps) Blood and lymphatic Very common Leukopaenia system disorders Neutropaenia Lymphopaenia Anaemia (including hypochromic) Common Thrombocytopaenia Febrile neutropaenia Uncommon Pancytopaenia Thrombocytosis Rare Bone marrow failure Immune system Uncommon Hypersensitivity disorders Anaphylactic reaction Rare Anaphylactoid reaction Metabolism and Very common Decreased appetite nutrition disorders Common Cachexia Dehydration Hypokalaemia Hyponatraemia Hypocalcaemia Uncommon Hyperkalaemia Hypomagnesaemia Psychiatric disorders Common Confusional state Anxiety Depression Insomnia Nervous system Common Neuropathy peripheral disorders Peripheral sensory neuropathy Neuralgia Paraesthesia Hypoaesthesia Dysgeusia Headache Lethargy Dizziness Uncommon Polyneuropathy Convulsion Syncope Dysaesthesia Somnolence Eye disorders Common Conjunctivitis Uncommon Vision blurred Lacrimation increased Rare Retinitis Cardiac disordersa Common Tachycardia Uncommon Palpitations Cardiac arrest Cardiac failure Cardiac failure congestive Cardiomyopathy

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11–12

HOS-085575 · Präparat HOS-083155

11  Cardiotoxicity Rare Ventricular arrhythmia Bundle branch block right Conduction disorder Atrioventricular block Cyanosis Vascular disorders Common Hypertension Hypotension Flushing Uncommon Pulmonary embolism Infusion site necrosis (including soft tissue necrosis and skin necrosis) Phlebitis Orthostatic hypotension Rare Thrombophlebitis Venous thrombosis Vasodilatation Respiratory, thoracic Common Dyspnoea and mediastinal Dyspnoea exertional disorders Epistaxis Cough Uncommon Asthma Chest discomfort Rare Throat tightness Not Known Interstitial lung disease Gastrointestinal Very common Stomatitis disorders Nausea Vomiting Diarrhoea Constipation Common Gastritis Aphthous stomatitis Mouth ulceration Dyspepsia Dysphagia Oesophagitis Abdominal pain Abdominal pain upper Oral pain Dry mouth Uncommon Flatulence Gingivitis Rare Glossitis Lip ulceration Skin and subcutaneous Very common Palmar plantar erythrodysaesthesia tissue disorders syndromea Rash (including erythematous, maculo-papular, and papular) Alopecia Common Skin exfoliation Blister Dry skin Erythema Pruritus

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 12–13

HOS-085576 · Präparat HOS-083155

12  Hyperhidrosis Skin hyperpigmentation Uncommon Dermatitis Dermatitis exfoliative Acne Skin ulcer Dermatitis allergic Urticaria Skin discolouration Petechiae Pigmentation disorder Nail disorder Rare Toxic epidermal necrolysis Erythema multiforme Dermatitis bullous Lichenoid keratosis Not known Stevens-Johnson syndromeb Musculoskeletal and Very common Musculoskeletal pain (including connective tissue musculoskeletal chest pain, back pain, pain disorders in extremity) Common Muscle spasms Myalgia Arthralgia Bone pain Uncommon Muscular weakness Renal and urinary Common Dysuria disorders Not Known Renal-limited thrombotic microangiopathy Reproductive disorders Uncommon Breast pain Rare Vaginal infection Scrotal erythema General disorders and Very common Pyrexia administration site Fatigue conditions Common Infusion-related reaction Pain Chest pain Influenza-like illness Chills Mucosal inflammation Asthenia Malaise Oedema Oedema peripheral Uncommon Administration site extravasation Injection site reaction Face oedema Hyperthermia Rare Mucous membrane disorder Investigations Common Weight decreased Uncommon Ejection fraction decreased Rare Liver function test abnormal (including Blood bilirubin increased, Alanine aminotransferase increased and Aspartate aminotransferase increased)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 13–14

HOS-085577 · Präparat HOS-083155

13  Blood creatinine increased Injury, poisoning and Uncommon Radiation recall phenomenona procedural complications a See Description of selected adverse reactions b Post-marketing adverse reaction

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14

HOS-085578 · Präparat HOS-083155

Description of selected adverse reactions Palmar plantar erythrodysaesthesia The most common undesirable effect reported in breast/ovarian clinical trials was palmar-plantar erythrodysesthesia (PPE). The overall incidence of PPE reported was 41.3% and 51.1% in the ovarian and breast clinical trials, respectively. These effects were mostly mild, with severe (grade 3) cases reported in 16.3% and 19.6% of patients. The reported incidence of life-threatening (grade 4) cases was < 1%. PPE infrequently resulted in permanent treatment discontinuation (1.9% and 10.8%). PPE was reported in 16% of multiple myeloma patients treated with Caelyx pegylated liposomal plus bortezomib combination therapy. Grade 3 PPE was reported in 5% of patients. No grade 4 PPE was reported. The rate of PPE was substantially lower in the AIDS-KS population (1.3% all grade, 0.4% grade 3 PPE, no grade 4 PPE). See section 4.4.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14

HOS-085579 · Präparat HOS-083155

Opportunistic infections Respiratory undesirable effects commonly occurred in clinical studies of Caelyx pegylated liposomal and may be related to opportunistic infections (OI’s) in the AIDS population. Opportunistic infections are observed in KS patients after administration with Caelyx pegylated liposomal, and are frequently observed in patients with HIV induced immunodeficiency. The most frequently observed OI’s in clinical studies were candidiasis, cytomegalovirus, herpes simplex, Pneumocystis jirovecii pneumonia, and mycobacterium avium complex.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Caelyx pegylated liposomal

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14

HOS-085580 · Präparat HOS-083155

Cardiac toxicity An increased incidence of congestive heart failure is associated with doxorubicin therapy at cumulative lifetime doses > 450 mg/m2 or at lower doses for patients with cardiac risk factors. Endomyocardial biopsies on nine of ten AIDS-KS patients receiving cumulative doses of Caelyx pegylated liposomal greater than 460 mg/m2 indicate no evidence of anthracycline-induced cardiomyopathy. The recommended dose of Caelyx pegylated liposomal for AIDS-KS patients is 20 mg/m2 every two-to-three weeks. The cumulative dose at which cardiotoxicity would become a concern for these AIDS-KS patients (> 400 mg/m2) would require more than 20 courses of Caelyx pegylated liposomal therapy over 40 to 60 weeks.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.